May 8, 2023 09:00 AM EDT
Deals
Bioregnum
R&D

When is a pre­clin­i­cal drug worth a moth­er lode of cash? This top 20 list of­fers a few an­swers

When Ver­tex is in­tent on a tar­get, the ex­ecs are known to splash out big time for ex­per­i­men­tal prod­ucts.

That gung-ho spir­it was on full …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

J&J re­ports dura­bil­i­ty da­ta for blad­der can­cer 'pret­zel' drug af­ter FDA fil­ing

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times